A Perspective on Nanoparticle Universal Influenza Vaccines

被引:35
|
作者
Deng, Lei [1 ]
Wang, Bao-Zhong [1 ]
机构
[1] Georgia State Univ, Ctr Inflammat Immun & Infect, 145 Piedmont Ave SE, Atlanta, GA 30302 USA
来源
ACS INFECTIOUS DISEASES | 2018年 / 4卷 / 12期
基金
美国国家卫生研究院;
关键词
prophylaxis; virus-like particle; self-assembling; long-lasting; headless hemagglutinin; matrix protein 2; VIRUS-LIKE PARTICLES; IMPROVED CROSS-PROTECTION; GOLD NANOPARTICLES; IMMUNE-RESPONSES; HEMAGGLUTININ TRIMERS; EXTRACELLULAR DOMAIN; ALVEOLAR MACROPHAGES; MONOCLONAL-ANTIBODY; PANDEMIC INFLUENZA; MATRIX PROTEIN-2;
D O I
10.1021/acsinfecdis.8b00206
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Annually recurring seasonal influenza causes massive economic loss and poses severe threats to public health worldwide. The current seasonal influenza vaccines are the most effective means of preventing influenza infections but possess major weaknesses. Seasonal influenza vaccines require annual updating of the vaccine strains. However, it is an unreachable task to accurately predict the future circulating strains. Vaccines with mismatched strains dramatically compromise the vaccine efficacy. In addition, the seasonal influenza vaccines are ineffective against an unpredictable pandemic. A universal influenza vaccine would overcome these weaknesses of the seasonal vaccines and abolish the threat of influenza pandemics. One approach under investigation is to design influenza vaccine immunogens based on conserved, type-specific amino acid sequences and conformational epitopes, rather than strain-specific. Such vaccines can elicit broadly reactive humoral and cellular immunity. Universal influenza vaccine development has intensively employed nanotechnology because the structural and morphological properties of nanoparticles dramatically improve vaccine immunogenicity and the induced immunity duration. Layered protein nanoparticles can decrease off-target immune responses, fine-tune antigen recognition and processing, and facilitate comprehensive immune response induction. Herein, we review the designs of effective nanoparticle universal influenza vaccines, the recent discoveries of specific nanoparticle features that contribute to immunogenicity enhancement, and recent progress in clinical trials.
引用
收藏
页码:1656 / 1665
页数:19
相关论文
共 50 条
  • [1] A PERSPECTIVE ON NANOPARTICLE UNIVERSAL INFLUENZA VACCINES
    不详
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2019, 123 (03): : 445 - 445
  • [2] 'UNIVERSAL' INFLUENZA VACCINES
    不详
    CHEMICAL & ENGINEERING NEWS, 2016, : 24 - 24
  • [3] The surge of universal influenza vaccines
    Cassone, Antonio
    PATHOGENS AND GLOBAL HEALTH, 2017, 111 (02) : 57 - 58
  • [4] Towards universal influenza vaccines?
    Osterhaus, Ab
    Fouchier, Ron
    Rimmelzwaan, Guus
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2011, 366 (1579) : 2766 - 2773
  • [5] Universal influenza vaccines: Shifting to better vaccines
    Scorza, Francesco Berlanda
    Tsyetnitsky, Vadim
    Donnelly, John J.
    VACCINE, 2016, 34 (26) : 2926 - 2933
  • [6] Autoreactive potential of universal influenza vaccines
    McGargill, Maureen Ann
    Pillai, Meenu R.
    Chang, Ti-Cheng
    Crawford, Jeremy
    Keating, Rachael
    Labombarde, Jocelyn
    Lewis, Carlessia
    Guthmiller, Jenna
    Li, Quan-Zhen
    Wilson, Patrick C.
    Thomas, Paul
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [7] Progress in the Development of Universal Influenza Vaccines
    Sun, Wenqiang
    Luo, Tingrong
    Liu, Wenjun
    Li, Jing
    VIRUSES-BASEL, 2020, 12 (09):
  • [8] Universal influenza vaccines: a realistic option?
    de Vries, R. D.
    Altenburg, A. F.
    Rimmelzwaan, G. F.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 : S120 - S124
  • [9] Research and development of universal influenza vaccines
    Du, Lanying
    Zhou, Yusen
    Jiang, Shibo
    MICROBES AND INFECTION, 2010, 12 (04) : 280 - 286
  • [10] Universal influenza vaccines are futile when benchmarked against seasonal influenza vaccines
    Valkenburg, Sophie A.
    Poon, Leo L. M.
    LANCET INFECTIOUS DISEASES, 2022, 22 (06): : 750 - 751